Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1

Zhu,Kai‑Chang; Sun,Jian‑Mei; Shen,Jian‑Guo; Jin,Ji‑Zhong; Liu,Feng; Xu,Xiao‑Lin; Chen,Lin; Liu,Lin‑Tao; Lv,Jia‑Ju

doi:10.3892/ol.2015.3619

Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1

Authors:
- Kai‑Chang Zhu
- Jian‑Mei Sun
- Jian‑Guo Shen
- Ji‑Zhong Jin
- Feng Liu
- Xiao‑Lin Xu
- Lin Chen
- Lin‑Tao Liu
- Jia‑Ju Lv
View Affiliations

Affiliations: Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China, Department of Neonatology, Tongji Hospital, Tongji University, Shanghai 200065, P.R. China, Department of Urology, Shanghai Jiaotong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China
Published online on: August 18, 2015 https://doi.org/10.3892/ol.2015.3619
Pages: 2359-2365

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer presents high occurrence worldwide. Medicinal plants are a major source of novel and potentially therapeutic molecules; therefore, the aim of the present study was to investigate the possible anti‑prostate cancer activity of afzelin, a flavonol glycoside that was previously isolated from Nymphaea odorata. The effect of afzelin on the proliferation of androgen‑sensitive LNCaP and androgen‑independent PC‑3 cells was evaluated by performing a water soluble tetrazolium salt‑1 assay. In addition, the effect of afzelin on the cell cycle of the LNCaP and PC‑3 prostate cancer cell lines was evaluated. Western blot analysis was performed to evaluate the effect of afzelin on the kinases responsible for the regulation of actin organization. Afzelin was identified to inhibit the proliferation of LNCaP and PC3 cells, and block the cell cycle in the G0 phase. The anticancer activity of afzelin in these cells was determined to be due to inhibition of LIM domain kinase 1 expression. Thus, the in vitro efficacy of afzelin against prostate cancer is promising; however, additional studies on different animal models are required to substantiate its anticancer potential.

View Figures

View References

1	Lowe HI, Watson CT, Badal S, et al: Cycloartane-3,24,25-triol inhibits MRCKα kinase and demonstrates promising anti prostate cancer activity in vitro. Cancer Cell Int. 12:462012. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Berthold DR, Sternberg CN and Tannock IF: Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol. 23:8247–8252. 2005. View Article : Google Scholar : PubMed/NCBI
5	Diantini A, Subarnas A, Lestari K, et al: Kaempferol-3-O-rhamnoside isolated from the leaves of Schima wallichii Korth inhibits MCF-7 breast cancer cell proliferation through activation of the caspase cascade pathway. Oncol Lett. 3:1069–1072. 2012.PubMed/NCBI
6	Mao YW, Tseng HW, Liang WL, et al: Anti-inflammatory and free radial scavenging activities of the constituents isolated from Machilus zuihoensis. Molecules. 16:9451–9466. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hall A: Rho GTPases and the actin cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar : PubMed/NCBI
8	Heikkila T, Wheatley E, Crighton D, et al: Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion. PloS One. 6:e248252011. View Article : Google Scholar : PubMed/NCBI
9	Jaffe AB and Hall A: Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 21:247–269. 2005. View Article : Google Scholar : PubMed/NCBI
10	Wilkinson S, Paterson HF and Marshall CJ: Cdc42-MRCK and Rho-ROCK signaling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol. 7:255–261. 2005. View Article : Google Scholar : PubMed/NCBI
11	Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer. 81:682–687. 1999. View Article : Google Scholar : PubMed/NCBI
12	Riento K and Ridley AJ: Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 4:446–456. 2003. View Article : Google Scholar : PubMed/NCBI
13	Nakajima M, Hayashi K, Egi Y, et al: Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol. 52:319–324. 2003. View Article : Google Scholar : PubMed/NCBI
14	Nakajima M, Hayashi K, Katayama K, et al: Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol. 459:113–120. 2003. View Article : Google Scholar : PubMed/NCBI
15	Nakajima M, Katayama K, Tamechika I, et al: WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motiltiy. Clin Exp Pharmacol Physiol. 30:457–463. 2003. View Article : Google Scholar : PubMed/NCBI
16	Genda T, Sakamoto M, Ichida T, et al: Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology. 30:1027–1036. 1999. View Article : Google Scholar : PubMed/NCBI
17	Takamura M, Sakamoto M, Genda T, et al: Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology. 33:577–581. 2001. View Article : Google Scholar : PubMed/NCBI
18	Ying H, Biroc SL, Li WW, et al: The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 5:2158–2164. 2006. View Article : Google Scholar : PubMed/NCBI
19	Bemis DL, Capodice JL, Desai M, et al: A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res. 10:5282–5292. 2004. View Article : Google Scholar : PubMed/NCBI
20	Ngamwongsatit P, Banada PP, Panbangred W and Bhunia AK: WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapiddetection of toxigenic Bacillus species using CHO cell line. J Microbiol Meth. 73:211–215. 2008. View Article : Google Scholar
21	Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563–572. 2002. View Article : Google Scholar : PubMed/NCBI
22	Olson MF and Sahai E: The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 26:273–287. 2009. View Article : Google Scholar : PubMed/NCBI
23	Banyard J, Anand-Apte B, Symons M and Zetter BR: Motility and invasion are differentially modulated by Rho family GTPases. Oncogene. 19:580–591. 2000. View Article : Google Scholar : PubMed/NCBI
24	Hall A: The cytoskeleton and cancer. Cancer Metastasis Rev. 28:5–14. 2009. View Article : Google Scholar : PubMed/NCBI
25	Morgan Fisher, Wewer UM and Yoneda A: Regulation of ROCK activity in cancer. J Histochem Cytochem. 61:185–198. 2013. View Article : Google Scholar : PubMed/NCBI
26	Amano M, Nakayama M and Kaibuchi K: Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 67:545–554. 2010. View Article : Google Scholar : PubMed/NCBI
27	Gurkar AU, Chu K, Raj L, et al: Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress. Nat Commun. 4:21892013. View Article : Google Scholar : PubMed/NCBI
28	Edwards DC, Sanders LC, Bokoch GM and Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1:253–259. 1999. View Article : Google Scholar : PubMed/NCBI
29	Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S and Mizuno K: Rho associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem. 275:3577–3582. 2000. View Article : Google Scholar : PubMed/NCBI
30	Sumi T, Matsumoto K, Shibuya A and Nakamura T: Activation of LIM kinases by myotonic dystrophy kinase-related Cdc42-binding kinase alpha. J Biol Chem. 276:23092–23096. 2001. View Article : Google Scholar : PubMed/NCBI
31	Dan C, Kelly A, Bernard O and Minden A: Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem. 276:32115–32121. 2001. View Article : Google Scholar : PubMed/NCBI
32	Vlecken DH and Bagowski CP: LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells. Zebrafish. 6:433–439. 2009. View Article : Google Scholar : PubMed/NCBI
33	Yoshioka K, Foletta V, Bernard O and Itoh K: A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA. 100:7247–7252. 2003. View Article : Google Scholar : PubMed/NCBI
34	Bagheri Yarmand, Mazumdar A, Sahin AA and Kumar R: LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer. 118:2703–2710. 2006. View Article : Google Scholar : PubMed/NCBI
35	Zhang Z, ElSohly HN, Li XC, et al: Phenolic compounds from Nymphaea odorat. J Nat Prod. 66:548–550. 2003. View Article : Google Scholar : PubMed/NCBI
36	Shin SW, Jung E, Kim S, Kim JH, Kim EG, Lee J and Park D: Antagonizing effects and mechanisms of afzelin against UVB-induced cell damage. PLoS One. 8:e619712013. View Article : Google Scholar : PubMed/NCBI
37	Zhou W and Nie X: Afzelin attenuates asthma phenotypes by downregulation of GATA3 in a murine model of asthma. Mol Med Rep. 12:71–76. 2015.PubMed/NCBI
38	Benitaha SA, Valeróna PF, Aelstb L, Marshallc CJ and Lacala JC: Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochimicaet Biophysica Acta. 1705:121–132. 2005.
39	Balasenthil S, Chen N, Lott ST, et al: A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Cancer Prev Res (Phila). 4:137–149. 2011. View Article : Google Scholar : PubMed/NCBI
40	Lefort K, Mandinova A, Ostano P, et al: Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCK-alpha kinases. Genes Dev. 21:562–577. 2007. View Article : Google Scholar : PubMed/NCBI
41	Pyeon D, Newton MA, Lambert PF, et al: Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res. 67:4605–4619. 2007. View Article : Google Scholar : PubMed/NCBI
42	Schlingemann J, Habtemichael N, Ittrich C, et al: Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. Lab Invest. 85:1024–1039. 2005. View Article : Google Scholar : PubMed/NCBI
43	Ginos MA, Page GP, Michalowicz BS, et al: Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 64:55–63. 2004. View Article : Google Scholar : PubMed/NCBI
44	Kim SM, Park YY, Park ES, et al: Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 5:e150742010. View Article : Google Scholar : PubMed/NCBI
45	Wang S, Zhan M, Yin J, et al: Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene. 25:3346–3356. 2006. View Article : Google Scholar : PubMed/NCBI
46	Hao Y, Triadafilopoulos G, Sahbaie P, et al: Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology. 131:925–933. 2006. View Article : Google Scholar : PubMed/NCBI
47	Kimchi ET, Posner MC, Park JO, et al: Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 65:3146–3154. 2005.PubMed/NCBI
48	Lourenço FC, Munro J, Brown J, et al: Reduced LIMK2 expression in colorectal cancer reflects its role in limiting stem cell proliferation. Gut. 63:480–493. 2014. View Article : Google Scholar : PubMed/NCBI